PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.78), $0.29 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $24.04 million.

2017 Guidance:

For 2017, PTC expects to achieve ex-U.S. Translarna net sales between $105 and $125 million, assuming current exchange rates, representing continued strong growth year-over-year of its sustainable DMD business. This is driven by both increased penetration into the over 25 countries where Translarna is currently available as well as continued geographic expansion into new territories.
PTC is reviewing its guidance for 2017 operating expenses and ending cash in light of PTC\'s planned acquisition of Emflaza™ (deflazacort)

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.